Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer

By sjmartinez • September 12, 2024

Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer. J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02265-2. doi: 10.1016/j.jtho.2024.09.1379. Epub ahead of print. PMID: 39260522.

Tags: Cedars Sinai DoM, Hematology/Oncology, Publications

Related Posts

One-year outcomes of the RESILIA balloon-expandable transcatheter valve: survival, hemodynamics, and hypoattenuated leaflet thickening

Suruga K, Patel V, Guo Y, Shitan H, Ng D, Nagasaka T, Menda J, Singh A, Gheorghiu M, Patel D, Gupta A, Chakravarty T, Cheng[...]

Optimization of Image Quality for Quantitative Multi-Contrast Atherosclerosis Characterization (qMATCH): Comparison Between Transverse and Coronal Acquisitions

Hsu YC, Lu M, Llanes A, Keushkerian MJ, Nguyen KL, Johnson K, Altbach MI, Morris HD, DeMarco JK, Deshpande V, Mitsouras D, Saloner D, McNally[...]

Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US

Turagam MK, Aryana A, Day JD, Dukkipati SR, Hounshell T, Nair D, Natale A, Weiner S, Cheung JW, Chinitz L, Cuoco F, Daccarett M, Dandamudi[...]